Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer
|Pathologically Demonstrated Bladder Cancer||Other: Data acquisition and analysis|
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Analysis of the Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer|
- To determine the gene expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME antigens in pathologically demonstrated bladder cancer. [ Time Frame: Up to 1 year ]
|Study Start Date:||January 2008|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Other: Data acquisition and analysis
Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
There will be no procedure(s) or treatment(s) carried out on patients. All data and samples will be taken from those already stored at the investigation sites. Clinical data collected will include patient demographics (age, gender), Tumor, Node, Metastasis (staging system) [TNM stage], and histopathologic description only. Strict anonymity of patient data will be maintained.
This retrospective study is based upon the analysis of archived formalin-fixed paraffin-embedded tissue samples and patient-related data already available at the investigational site.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01706185
|GSK Investigational Site|
|Leuven, Belgium, 3000|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|